Bluefish Pharmaceuticals
Wojciech Stras is an accomplished professional with extensive experience in the pharmaceutical industry, currently serving as Country Manager at Bluefish Pharmaceuticals since January 2020. Wojciech's responsibilities include managing sales and marketing efforts, developing local strategies, and building partnerships across various business segments in Poland. Previous roles include Business Unit Manager for Ophthalmology and Oncology at Adamed Pharma, where Wojciech successfully managed outpatient and hospital specialty businesses, and Business Unit Director positions at Bristol-Myers Squibb, overseeing oncology, hematology, cardiovascular, and metabolic strategies. Wojciech possesses a Doctor's Degree in Oncology from the Medical University of Warsaw and a Doctor of Medicine from Wroclaw Medical University, complemented by a strong foundation in economics from Wroclaw University of Economics and Business.
This person is not in any offices
Bluefish Pharmaceuticals
Founded in Sweden, with its long tradition of industrial entrepreneurship, Bluefish Pharmaceuticals has become one of the most progressive generics pharmaceuticals companies. At Bluefish, we strive to make quality medicines accessible to more people. We create value in the full pharmaceutical value chain from developing to manufacturing and successfully marketing generic pharmaceuticals and we take pride in doing this in an innovative, responsible and cost-efficient way. Bluefish currently conducts operations in 19 countries in Europe and, over the next few years, will also expand outside Europe with the aim of becoming a global player. Our corporate culture and close collaboration with development and manufacturing partners are integral parts of our effort to deliver quality products at affordable prices. We offer a product portfolio consisting of a broad range of high quality generics for all major therapeutic areas. It is part of our long-term strategy to expand the product portfolio of off-patent blockbusters while at the same time offering a broader range of niche products within more narrow disease areas.